Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties-Reference-Cited by-同舟云学术

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Published:2018-05-04 Issue:1 Volume:54 Page:44-52
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Dreger Peter,Michallet Mauricette,Bosman Paul,Dietrich Sascha,Sobh Mohamad,Boumendil Ariane,Nagler Arnon,Scheid Christof,Cornelissen Jan,Niederwieser Dietger^ORCID,Müller Lutz,Vandenberghe Elizabeth,Scortechini Ilaria,Schoemans Helene^ORCID,Andersen Niels S.,Finke Jürgen,Russo Domenico,Ljungman Per^ORCID,Passweg Jakob,van Gelder Michel,Durakovic Nadira,Labussiere-Wallet Helene,Berg Tobias,Wulf Gerald,Bethge Wolfgang,Bunjes Donald,Stilgenbauer Stefan,Canepari Maria Elisa,Schaap Michel,Fox Christopher P.,Kröger Nicolaus,Montoto Silvia,Schetelig Johannes

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0207-4.pdf

Reference34 articles.

1. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

2. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the Era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32:3039–47.

3. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients. Ann Oncol. 2017;28:1050–6.

4. Davids MS. How should we sequence and combine novel therapies in CLL? Hematol Am Soc Hematol Educ Program. 2017;2017:346–53.

5. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. Indolente (niedrig maligne) Non-Hodgkin-Lymphome;Facharztwissen Hamatologie Onkologie;2024

3. Allogeneic Hematopoietic Stem Cell Transplant;Comprehensive Hematology and Stem Cell Research;2024

4. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2023-10-25

5. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma;Blood Advances;2023-08-11